Type:
Educational Exhibit
Keywords:
Neuroradiology brain, CNS, Nuclear medicine, PET, MR, CT, Contrast agent-intravenous, Staging, Treatment effects, Multidisciplinary cancer care, Cancer, Neoplasia
Authors:
J. J. Delgado Moraleda, P. Sopena-Novales, S. Brugger, P. Oliván Sasot, A. M. Yepes Agudelo, A. ALEGRE DELGADO; Valencia/ES
DOI:
10.1594/ecr2018/C-0245
Background
Differential diagnosis of brain focal lesions is complex and requires the use of multiple imaging techniques.
Benign lesions,
malignant lesions,
demyelination,
radionecrosis and metastases can produce similar imaging findings,
both on CT and MRI.
Regarding the metabolic study of this lesions,
it is frequent to find an increased glucose uptake in all of them,
regardless of they are benign lesions,
inflammatory or malignant lesions.
Therefore,
the PET glucose (FDG-PET) may show unspecific results.
To improve diagnosis,
there are new MRI techniques that provide greater structural and molecular information of the tumor: these are diffusion,
perfusion and spectroscopy.
Moreover,
there are new PET radiotracers that provide even more information about the lesions.
A particularly useful example is the case of Choline radiotracer for the study of brain tumors.